Navigation Links
UPDATE: Nile Therapeutics Announces Positive Phase 1a Results of CD-NP, a Selective NPR-B Agonist in Clinical Development for the Treatment of Heart Failure
Date:10/11/2007

BERKELEY, Calif., Oct. 11 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (OTC Bulletin Board: NILT), today announced results from a Phase 1a clinical study of CD-NP, Nile's selective NPR-B agonist being developed for the treatment of heart failure. The results of this study will be included in the Company's presentation today at the BIO Investor Forum in San Francisco, CA.

"The development of a peptide that has natriuretic and renal effects, with relatively little effect on blood pressure, is a potentially important achievement. The results of this trial in healthy volunteers have confirmed some of the hypotheses developed during the pre-clinical studies. We were particularly interested to see a clear, dose dependent increase in cGMP, which suggests the molecule activates the NPR receptors," commented Dr. Barry Massie, Professor of Medicine, University of California, San Francisco, Chief, Cardiology Section, San Francisco VA Hospital, and member of Nile's scientific advisory board.

Study Design

The Phase 1a study was conducted to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic profile of various doses of CD-NP compared to placebo over a four-hour infusion in 22 healthy volunteers. The study evaluated several pharmacodynamic variables which may translate into safety and efficacy in the heart failure population. Nile measured the effect of CD-NP on systemic blood pressure, urinary flow rate, urinary sodium excretion, serum potassium, renal function and cGMP, a secondary messenger of the target receptor and indicator of in-vivo activity.

Study Results

CD-NP was well tolerated with no serious adverse events and all subjects completed the four-hour infusion of placebo, 10, 17.5 or 25 ng/kg/min of CD-NP.

With respect to clinical and biomarker assessments, CD-NP (placebo, 10, 17.5 and 25 ng/kg/min) increased urine flow rate versus baseline (125%, 53%, 30% and 230% average change, respectively), increa
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) ... of Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ... its fiduciary duties to shareholders. On January ... website reporting that Advaxis had misrepresented the clinical data ...
(Date:1/23/2015)... SETAUKET, N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, ... where its Phase I trial of Lixte,s lead compound, LB‑100, ... institutions. John S. Kovach , M.D., the ... was planned to be completed at a single site. Accrual ...
(Date:1/23/2015)... Jan. 23, 2015 Gem Pharmaceuticals announced today that ... enrolled into the Company,s Phase 2 clinical trial.  This ... Gem,s lead compound, GPX-150 (an investigational medication), in approximately ... disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
(Date:1/22/2015)... 2015 The City of West Hollywood hosted a ... commemorate the 42nd anniversary of the Supreme Court decision Roe v. ... 42 years since the Roe vs. Wade decision and the fight ... as ever,” said City of West Hollywood Councilmember Abbe Land. “We ...
(Date:1/22/2015)... VogueQueen is a seasoned and trusted leader ... designers are thrilled to have it lead the wedding dress ... collection of prom dresses for the global market. , “The ... vision and he focuses on continuing the goal of operational ...
(Date:1/22/2015)... 2015 AngelWeddingDress, the premier women’s dress ... wedding dresses. View website of AngelWeddingDress.com to ... maternity wedding dresses online for a bridal party. AngelWeddingDress ... quality for them. Its maternity wedding dresses are specially ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo ... the federal multidistrict litigation underway in U.S. District Court, ... an Order dated January 20th, the Court has remanded ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Joan Lunden, ... keynote speaker at the upcoming 32nd Annual Miami ... Physicians’ Education Resource®, LLC (PER®) , shares that ... have gone undetected if she had not followed up ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
... of Governance, Privacy, Security and Policy Development to ... , , GREAT RIVER, N.Y., April ... of enterprise-wide software and services for health and ... with health information exchange (HIE) consulting firm Object ...
... (Nasdaq: DATA ), a technology and services ... trials industry, today reported a multi-year agreement with the ... newest member of DATATRAK,s CRO Connect Program(TM), Keypoint is ... and empower its staff to more efficiently manage both ...
... with Disability Awareness Leadership, InnovationPORTLAND, Maine, April 22 ... Portland, Maine-based not-for-profit organization dedicated to raising public ... the need to prepare for the potential financial ... retire as President of the CDA, effective May ...
... Germany, 22 April 2009 - Olivier Voinnet from the ... is awarded the 2009 EMBO Gold Medal. The researcher ... mechanisms and roles of gene silencing via RNA in ... Biology Organization (EMBO) recognizes the outstanding contributions of young ...
... to hold second annual Walk-a-thon event THIS SUMMERNEW YORK, April ... Flags, and Cure Kids Cancer have teamed up once again ... "A Walk In The Park" program. This unique walk-a-thon ... April 26 through July 26 offering local neighborhoods a distinct, ...
... importance of a gap between bad news and request , , ... to donate -- or not donate -- a dying relative,s ... and when it,s made are key, U.K. researchers have found. ... at the same time that relatives are told their loved ...
Cached Medicine News:Health News:Netsmart Technologies Announces Partnership With Health Information Exchange Consulting Firm Object Health 2Health News:Netsmart Technologies Announces Partnership With Health Information Exchange Consulting Firm Object Health 3Health News:Netsmart Technologies Announces Partnership With Health Information Exchange Consulting Firm Object Health 4Health News:Keypoint Joins DATATRAK's CRO Connect Program(TM) 2Health News:Keypoint Joins DATATRAK's CRO Connect Program(TM) 3Health News:Keypoint Joins DATATRAK's CRO Connect Program(TM) 4Health News:President of Council for Disability Awareness Announces Retirement 2Health News:Olivier Voinnet awarded 2009 EMBO Gold Medal 2Health News:Olivier Voinnet awarded 2009 EMBO Gold Medal 3Health News:Six Flags Friends Invites Guests to Help Cure Kids Cancer by Taking 'A Walk In The Park' 2Health News:Six Flags Friends Invites Guests to Help Cure Kids Cancer by Taking 'A Walk In The Park' 3Health News:Six Flags Friends Invites Guests to Help Cure Kids Cancer by Taking 'A Walk In The Park' 4Health News:Timing May Matter in Organ Donation Decisions 2
Used to introduce balloon, closed and non-tapered end catheters and other devices for intervention....
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
Medicine Products: